查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1904616

再生醫學和幹細胞療法市場預測至2032年：按產品類型、治療方法、細胞來源、適應症、應用、最終用戶和地區分類的全球分析

Regenerative Medicine & Stem Cell Therapy Market Forecasts to 2032 - Global Analysis By Product, Therapy Type, Cell Source, Indication, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，預計到 2025 年，全球再生醫學和幹細胞治療市場價值將達到 414.6 億美元，到 2032 年將達到 1,229.6 億美元，在預測期內的複合年成長率為 16.8%。

再生醫學和幹細胞療法是醫療保健領域的創新分支，專注於修復、替換和再生受損的組織和器官。這些治療方法利用幹細胞分化成特定細胞類型的特性，旨在恢復因創傷、疾病或老齡化而喪失的正常功能。該領域融合了生物學、組織工程和臨床醫學的原理，為神經退化性疾病、心血管疾病和肌肉骨骼損傷等疾病開發創新療法。再生醫學超越了症狀管理，力求從根本上治癒身體，從而實現長期康復並提高生活品質。

加速監管核准和臨床成功

再生醫學和幹細胞療法市場的發展主要得益於監管核准速度的加速和臨床療效的提升。世界各國政府和衛生部門正在簡化創新治療方法的核准流程，縮短有前景的治療方法上市時間。針對神經退化性疾病疾病和心血管疾病等病症，基於幹細胞的治療方法已在臨床試驗中證實了其療效和安全性，這進一步提振了投資者的信心。監管方面的進步正在促進研究，擴大先進治療方法的可及性，並加速全球市場的整體成長。

高昂的醫療和研發成本

再生醫學和幹細胞療法市場面臨許多限制因素，其中治療和研發成本居高不下是主要原因。幹細胞療法的研發需要複雜的實驗室流程和大量的基礎設施投資，這無疑增加了整體支出。這些成本限制了患者獲得治療的機會，並減緩了新興市場對該療法的接受度。此外，醫療服務提供者和保險公司承擔的沉重經濟負擔也會阻礙該療法的廣泛應用，因此，如何提高治療的可及性成為該行業維持永續成長必須解決的關鍵挑戰。

個人化和精準醫療的發展趨勢

個人化和精準醫療為市場帶來了巨大的機會。根據個體的基因和分子特徵客製化治療方法，可以提高療效、減少副作用並改善治療結果。基因組學、生物標記識別和生物資訊學的進步正在推動這一向個人化醫療的轉變。將幹細胞治療方法與精準醫療方法結合，可以針對特定的疾病機制，從而提供高度專業化的解決方案，並擴大市場潛力，以改善患者的治療效果，尤其是在腫瘤和慢性退化性疾病領域。

監理合規挑戰

再生醫學和幹細胞療法市場面臨來自嚴格監管和合規要求的威脅。各地法規結構的差異為臨床試驗、生產規範和產品核可的標準化帶來了挑戰。違規可能導致核准延遲、經濟處罰以及企業聲譽受損。此外，細胞療法指南的不斷更新也要求製造商和研究人員持續調整。這種監管複雜性會減緩創新步伐，限制市場准入，並限制全球規模化發展。

新冠疫情的影響

新冠疫情對市場產生了重大影響。幹細胞療法在免疫調節和肺部修復方面的研究加速推進，而封鎖措施和資源重新分配則延誤了常規臨床試驗和擇期治療。供應鏈中斷影響了實驗室試劑和幹細胞產品的供應。然而，這場危機也凸顯了再生醫學在治療呼吸系統併發症的潛力，並提高了人們對創新治療方法的興趣。最終，疫情凸顯了建構具有韌性的醫療基礎設施對於市場持續發展的重要性。

預計在預測期內，順勢療法領域將佔據最大的市場佔有率。

預計在預測期內，異體移植療法將佔據最大的市場佔有率，因為它具有標準化生產、縮短製造時間以及能夠利用單一細胞來源治療多名患者等優勢。異體移植療法在血液系統疾病、心血管疾病和免疫力缺乏治療領域的臨床應用日益廣泛，進一步推動了市場需求。此外，對品管和安全標準的日益重視也增強了人們對異體移植解決方案的信任，從而支持了市場的強勁成長。

預計在預測期內，腫瘤治療領域將達到最高的複合年成長率。

預計在預測期內，腫瘤治療領域將實現最高成長率，因為它為骨髓惡性腫瘤和固態腫瘤提供標靶治療方法，有助於提高存活率並降低復發風險。臨床研究投入的不斷增加，以及監管機構對創新癌症療法的支持，正在加速這些療法的應用。利用幹細胞和基因編輯技術的個人化腫瘤治療進一步提高了療效，使該領域成為全球再生醫學市場的主要成長動力。

比最大的地區

預計亞太地區將在預測期內佔據最大的市場佔有率，這主要得益於中國、日本和韓國等國家在幹細胞研究領域的領先舉措，以及政府的利好政策和資金籌措支持。慢性病盛行率的上升和人口老化正在推動再生醫學的需求。此外，該地區擁有技術精湛的醫療專業人員和先進的醫療設施，這使得創新治療方法得以廣泛應用，從而鞏固了其在全球市場的主導地位。

年複合成長率最高的地區

預計北美地區在預測期內將實現最高的複合年成長率，這得益於其完善的法規結構，該框架支持新型治療方法的臨床試驗和商業化。醫療服務提供者和患者的高度認知，以及龐大的醫療支出，正在推動市場普及。幹細胞療法領域的持續創新，包括CAR-T療法和基因修飾療法，使北美成為高成長市場，並推動了先進再生醫學解決方案的開發和應用。

免費客製化服務

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 最多三家新增市場參與企業進行全面分析
    • 主要參與企業（最多3家公司）的SWOT分析
  • 區域細分
    • 根據客戶要求，對主要國家進行市場估算和預測，並計算複合年成長率（註：可行性需確認）。
  • 競爭標竿分析
    • 從產品系列、地域覆蓋範圍和策略聯盟等方面對主要參與企業進行基準分析

目錄

第1章執行摘要

第2章 前言

  • 摘要
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球再生醫學和幹細胞療法市場（按產品分類）

  • 幹細胞產品
    • 胚胎幹細胞
    • 誘導性多功能幹細胞
    • 成體幹細胞
  • 基因改造細胞療法
  • 組織工程產品
  • 細胞免疫療法

6. 全球再生醫學和幹細胞療法市場（依治療方法）

  • 自體療法
  • 順勢療法

7. 全球再生醫學和幹細胞療法市場（按細胞來源分類）

  • 骨髓來源細胞
  • 周邊血幹細胞
  • 脂肪組織來源細胞
  • 胎盤來源細胞
  • 臍帶血衍生細胞

8. 全球再生醫學和幹細胞療法市場（按適應症分類）

  • 腫瘤學
  • 眼科
  • 肌肉骨骼疾病
  • 自體免疫疾病
  • 循環系統疾病
  • 皮膚病學和創傷護理
  • 神經系統疾病

9. 全球再生醫學和幹細胞療法市場（按應用領域分類）

  • 研究用途
  • 藥物發現與開發
  • 臨床應用

第10章 全球再生醫學和幹細胞治療市場（按最終用戶分類）

  • 醫院和診所
  • 研究所
  • 政府機構
  • 製藥公司

第11章 全球再生醫學和幹細胞治療市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章：企業概況

  • Mesoblast Limited
  • Novartis AG
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Smith & Nephew plc
  • Baxter International Inc.
  • Organogenesis Holdings Inc.
  • Stryker Corporation
  • Integra LifeSciences Holdings Corporation
  • Bluebird Bio, Inc.
  • Medipost Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • Anterogen Co., Ltd.
  • Vericel Corporation
  • Pluristem Therapeutics Inc.
Product Code: SMRC32982

According to Stratistics MRC, the Global Regenerative Medicine & Stem Cell Therapy Market is accounted for $41.46 billion in 2025 and is expected to reach $122.96 billion by 2032 growing at a CAGR of 16.8% during the forecast period. Regenerative medicine and stem cell therapy represent a revolutionary branch of medical science focused on repairing, replacing, or regenerating damaged tissues and organs. By harnessing the unique properties of stem cells cells capable of developing into specialized cell types these therapies aim to restore normal function lost due to injury, disease, or aging. This field combines principles from biology, tissue engineering, and clinical medicine to create innovative treatments for conditions such as neurodegenerative disorders, cardiovascular diseases, and musculoskeletal injuries. Beyond symptom management, regenerative medicine aspires to heal the body at its core, offering the promise of long-term recovery and improved quality of life.

Market Dynamics:

Driver:

Accelerating Regulatory Approvals & Clinical Successes

The regenerative medicine and stem cell therapy market is being propelled by faster regulatory approvals and increasing clinical successes. Governments and health authorities worldwide are streamlining pathways for innovative therapies, reducing time-to-market for promising treatments. Successful clinical trials demonstrating efficacy and safety of stem cell-based interventions for diseases such as neurodegenerative disorders and cardiovascular conditions further bolster investor confidence. This regulatory momentum encourages research, making advanced therapies more accessible and accelerating the overall growth of the global market.

Restraint:

High Treatment & R&D Costs

Regenerative medicine and stem cell therapy market faces significant restraints due to high treatment and research costs. Developing stem cell therapies involves complex laboratory processes and substantial infrastructure investments, which increase overall expenditure. These costs often limit patient accessibility and slow adoption in emerging markets. Additionally, the high financial burden on healthcare providers and insurers can hinder widespread implementation, making affordability a critical challenge that the industry must address to sustain long-term growth.

Opportunity:

Personalized & Precision Medicine Trends

Personalized and precision medicine presents a significant opportunity for the market. By tailoring therapies to an individual's genetic and molecular profile, treatments become more effective, minimizing adverse effects and improving outcomes. Advances in genomics, biomarker identification, and bioinformatics are driving this shift toward individualized healthcare. Stem cell-based therapies integrated with precision medicine approaches can target specific disease mechanisms, creating highly specialized solutions, expanding market potential, and enhancing patient outcomes, particularly in oncology and chronic degenerative diseases.

Threat:

Regulatory & Compliance Challenges

The regenerative medicine and stem cell therapy market faces threats from stringent regulatory and compliance requirements. Diverse regulatory frameworks across regions create challenges in standardizing clinical trials, manufacturing practices, and product approvals. Noncompliance can result in delayed approvals, financial penalties, and reputational risks for companies. Moreover, evolving guidelines for cell-based therapies require continuous adaptation by manufacturers and researchers. These regulatory complexities can slow innovation, restrict market entry, and limit global scalability.

Covid-19 Impact:

The COVID-19 pandemic significantly influenced the market. While research on stem cell therapies for immune modulation and lung repair accelerated, routine clinical trials and elective treatments were delayed due to lockdowns and resource reallocation. Supply chain disruptions affected the availability of laboratory reagents and stem cell products. However, the crisis highlighted the potential of regenerative therapies in addressing respiratory complications, increasing interest in innovative treatments. The pandemic ultimately underscored the importance of resilient healthcare infrastructure for market continuity.

The allogeneic therapies segment is expected to be the largest during the forecast period

The allogeneic therapies segment is expected to account for the largest market share during the forecast period because these therapies offer advantages such as standardized production, reduced manufacturing time, and the ability to treat multiple patients from a single cell source. Growing clinical adoption for treating conditions like hematological disorders, cardiovascular diseases, and immunological deficiencies further fuels market demand. The increasing focus on quality control and safety standards also strengthens confidence in allogeneic solutions, supporting robust market expansion.

The oncology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oncology segment is predicted to witness the highest growth rate, as they offer targeted treatment approaches for hematological malignancies and solid tumors, improving survival rates and reducing relapse risks. Increased investment in clinical research, coupled with regulatory support for innovative cancer therapies, is accelerating adoption. Personalized oncology treatments leveraging stem cells and gene editing technologies further enhance efficacy, positioning this segment as a key driver of growth in the global regenerative medicine market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, because Countries such as China, Japan, and South Korea are leading in stem cell research, supported by favorable government policies and funding initiatives. The growing prevalence of chronic diseases, coupled with an aging population, drives demand for regenerative therapies. Additionally, the presence of skilled healthcare professionals and advanced medical facilities enables the widespread adoption of innovative treatments, reinforcing the region's dominance in the global market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to region benefits from a well-established regulatory framework that supports clinical trials and commercialization of novel therapies. High awareness among healthcare providers and patients, coupled with significant healthcare spending, fuels market adoption. Continuous innovation in stem cell therapies including CAR-T and gene-modified treatments positions North America as a high-growth market, driving the development and accessibility of advanced regenerative solutions.

Key players in the market

Some of the key players in Regenerative Medicine & Stem Cell Therapy Market include Mesoblast Limited, Novartis AG, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Smith & Nephew plc, Baxter International Inc., Organogenesis Holdings Inc., Stryker Corporation, Integra LifeSciences Holdings Corporation, Bluebird Bio, Inc., Medipost Co., Ltd., Thermo Fisher Scientific Inc., Siemens Healthineers, Vericel Corporation, and Pluristem Therapeutics Inc.

Key Developments:

In November 2025, Siemens Healthineers introduced Syngo Carbon 2.0, an upgraded enterprise imaging platform. The launch integrates multimodal imaging data, AI-powered workflow automation, and cloud-based collaboration, designed to streamline radiology operations and improve diagnostic accuracy across global healthcare systems.

In October 2025, Siemens Healthineers expanded its collaboration with Varian and multiple oncology centers to accelerate precision therapy solutions. The joint venture integrates imaging, radiation therapy, and AI-driven planning tools, aiming to improve cancer treatment outcomes and strengthen Siemens' leadership in oncology care.

Products Covered:

  • Stem Cell Products
  • Gene-Modified Cell Therapies
  • Tissue-Engineered Products
  • Cell-Based Immunotherapies

Therapy Types Covered:

  • Autologous Therapies
  • Allogeneic Therapies

Cell Sources Covered:

  • Bone Marrow-Derived Cells
  • Peripheral Blood Stem Cells
  • Adipose Tissue-Derived Cells
  • Placenta-Derived Cells
  • Umbilical Cord Blood Cells

Indications Covered:

  • Oncology
  • Ophthalmology
  • Musculoskeletal Disorders
  • Autoimmune Diseases
  • Cardiovascular Diseases
  • Dermatology and Wound Care
  • Neurological Disorders

Applications Covered:

  • Research Applications
  • Drug Discovery and Development
  • Clinical Applications

End Users Covered:

  • Hospitals and Clinics
  • Research Institutes
  • Government Organizations
  • Pharmaceutical Companies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Regenerative Medicine & Stem Cell Therapy Market, By Product

  • 5.1 Introduction
  • 5.2 Stem Cell Products
    • 5.2.1 Embryonic Stem Cells
    • 5.2.2 Induced Pluripotent Stem Cells
    • 5.2.3 Adult Stem Cells
  • 5.3 Gene-Modified Cell Therapies
  • 5.4 Tissue-Engineered Products
  • 5.5 Cell-Based Immunotherapies

6 Global Regenerative Medicine & Stem Cell Therapy Market, By Therapy Type

  • 6.1 Introduction
  • 6.2 Autologous Therapies
  • 6.3 Allogeneic Therapies

7 Global Regenerative Medicine & Stem Cell Therapy Market, By Cell Source

  • 7.1 Introduction
  • 7.2 Bone Marrow-Derived Cells
  • 7.3 Peripheral Blood Stem Cells
  • 7.4 Adipose Tissue-Derived Cells
  • 7.5 Placenta-Derived Cells
  • 7.6 Umbilical Cord Blood Cells

8 Global Regenerative Medicine & Stem Cell Therapy Market, By Indication

  • 8.1 Introduction
  • 8.2 Oncology
  • 8.3 Ophthalmology
  • 8.4 Musculoskeletal Disorders
  • 8.5 Autoimmune Diseases
  • 8.6 Cardiovascular Diseases
  • 8.7 Dermatology and Wound Care
  • 8.8 Neurological Disorders

9 Global Regenerative Medicine & Stem Cell Therapy Market, By Application

  • 9.1 Introduction
  • 9.2 Research Applications
  • 9.3 Drug Discovery and Development
  • 9.4 Clinical Applications

10 Global Regenerative Medicine & Stem Cell Therapy Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals and Clinics
  • 10.3 Research Institutes
  • 10.4 Government Organizations
  • 10.5 Pharmaceutical Companies

11 Global Regenerative Medicine & Stem Cell Therapy Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Mesoblast Limited
  • 13.2 Novartis AG
  • 13.3 Astellas Pharma Inc.
  • 13.4 Takeda Pharmaceutical Company Limited
  • 13.5 Smith & Nephew plc
  • 13.6 Baxter International Inc.
  • 13.7 Organogenesis Holdings Inc.
  • 13.8 Stryker Corporation
  • 13.9 Integra LifeSciences Holdings Corporation
  • 13.10 Bluebird Bio, Inc.
  • 13.11 Medipost Co., Ltd.
  • 13.12 Thermo Fisher Scientific Inc.
  • 13.13 Anterogen Co., Ltd.
  • 13.14 Vericel Corporation
  • 13.15 Pluristem Therapeutics Inc.

List of Tables

  • Table 1 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Stem Cell Products (2024-2032) ($MN)
  • Table 4 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Embryonic Stem Cells (2024-2032) ($MN)
  • Table 5 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Induced Pluripotent Stem Cells (2024-2032) ($MN)
  • Table 6 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Adult Stem Cells (2024-2032) ($MN)
  • Table 7 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Gene-Modified Cell Therapies (2024-2032) ($MN)
  • Table 8 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Tissue-Engineered Products (2024-2032) ($MN)
  • Table 9 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Cell-Based Immunotherapies (2024-2032) ($MN)
  • Table 10 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 11 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Autologous Therapies (2024-2032) ($MN)
  • Table 12 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Allogeneic Therapies (2024-2032) ($MN)
  • Table 13 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Cell Source (2024-2032) ($MN)
  • Table 14 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Bone Marrow-Derived Cells (2024-2032) ($MN)
  • Table 15 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Peripheral Blood Stem Cells (2024-2032) ($MN)
  • Table 16 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Adipose Tissue-Derived Cells (2024-2032) ($MN)
  • Table 17 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Placenta-Derived Cells (2024-2032) ($MN)
  • Table 18 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Umbilical Cord Blood Cells (2024-2032) ($MN)
  • Table 19 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Indication (2024-2032) ($MN)
  • Table 20 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 21 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Ophthalmology (2024-2032) ($MN)
  • Table 22 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Musculoskeletal Disorders (2024-2032) ($MN)
  • Table 23 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Autoimmune Diseases (2024-2032) ($MN)
  • Table 24 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 25 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Dermatology and Wound Care (2024-2032) ($MN)
  • Table 26 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Neurological Disorders (2024-2032) ($MN)
  • Table 27 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Application (2024-2032) ($MN)
  • Table 28 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Research Applications (2024-2032) ($MN)
  • Table 29 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Drug Discovery and Development (2024-2032) ($MN)
  • Table 30 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Clinical Applications (2024-2032) ($MN)
  • Table 31 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By End User (2024-2032) ($MN)
  • Table 32 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Hospitals and Clinics (2024-2032) ($MN)
  • Table 33 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 34 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Government Organizations (2024-2032) ($MN)
  • Table 35 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.